$SGMO
SANGAMO THERAPEUTICS, INC

2017 Q4 Form 10-K Financial Statement

#000156459018004163 Filed on March 01, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2017 Q2
Revenue $13.08M $11.81M $8.253M
YoY Change 46.57% 318.42% 122.93%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.470M $6.420M $6.040M
YoY Change 53.7% 27.89% -45.54%
% of Gross Profit
Research & Development $19.38M $18.43M $14.98M
YoY Change 39.52% 8.32% -23.0%
% of Gross Profit
Depreciation & Amortization $500.0K $400.0K $300.0K
YoY Change 66.67% 100.0% 0.0%
% of Gross Profit
Operating Expenses $26.84M $24.85M $21.02M
YoY Change 43.15% 12.79% -31.18%
Operating Profit -$13.04M
YoY Change
Interest Expense $680.0K $680.0K $280.0K
YoY Change 209.09% 183.33% 16.67%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$13.09M -$12.35M -$12.49M
YoY Change 36.21% -34.89% -53.05%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$13.09M -$12.35M -$12.49M
YoY Change 36.02% -34.86% -53.0%
Net Earnings / Revenue -100.11% -104.59% -151.35%
Basic Earnings Per Share
Diluted Earnings Per Share -$154.2K -$147.5K -$172.2K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 Q3 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $243.3M $236.7M $249.9M
YoY Change 70.7% 52.62% 45.04%
Cash & Equivalents $49.83M $29.89M $69.84M
Short-Term Investments $193.5M $206.8M $180.1M
Other Short-Term Assets $1.500M $1.700M $2.000M
YoY Change -16.67% 13.33% 53.85%
Inventory
Prepaid Expenses
Receivables $3.343M $3.400M $3.500M
Other Receivables $300.0K $500.0K $300.0K
Total Short-Term Assets $248.4M $242.3M $255.7M
YoY Change 66.04% 62.84% 45.16%
LONG-TERM ASSETS
Property, Plant & Equipment $31.07M $8.500M $8.300M
YoY Change 370.7% 73.47% 174.38%
Goodwill $1.585M
YoY Change 0.0%
Intangibles $0.00
YoY Change
Long-Term Investments $1.000M $16.30M $16.30M
YoY Change 71.58%
Other Assets $1.181M $1.000M $1.000M
YoY Change 598.82% 400.0% 584.93%
Total Long-Term Assets $38.34M $27.50M $27.30M
YoY Change 362.44% 69.75% 474.01%
TOTAL ASSETS
Total Short-Term Assets $248.4M $242.3M $255.7M
Total Long-Term Assets $38.34M $27.50M $27.30M
Total Assets $286.7M $269.8M $283.0M
YoY Change 81.61% 63.52% 56.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.00K $10.10M $9.200M
YoY Change -99.38% 60.32% 31.43%
Accrued Expenses $5.500M $4.500M $2.900M
YoY Change 89.66% 60.71% 31.82%
Deferred Revenue $28.35M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.86M $42.90M $41.70M
YoY Change 237.51% 208.63% 188.38%
LONG-TERM LIABILITIES
Long-Term Debt $24.70M $3.900M $3.900M
YoY Change 533.33% 69.57% 1850.0%
Other Long-Term Liabilities $29.20M $36.30M $43.40M
YoY Change 548.89% 626.0% 600.0%
Total Long-Term Liabilities $53.90M $40.20M $47.30M
YoY Change 541.67% 450.68% 639.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.86M $42.90M $41.70M
Total Long-Term Liabilities $53.90M $40.20M $47.30M
Total Liabilities $98.84M $83.10M $89.00M
YoY Change 355.57% 293.84% 326.18%
SHAREHOLDERS EQUITY
Retained Earnings -$495.5M
YoY Change 12.38%
Common Stock $683.7M
YoY Change 18.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $187.9M $186.7M $194.0M
YoY Change
Total Liabilities & Shareholders Equity $286.7M $269.8M $283.0M
YoY Change 81.61% 63.51% 56.43%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2017 Q2
OPERATING ACTIVITIES
Net Income -$13.09M -$12.35M -$12.49M
YoY Change 36.02% -34.86% -53.0%
Depreciation, Depletion And Amortization $500.0K $400.0K $300.0K
YoY Change 66.67% 100.0% 0.0%
Cash From Operating Activities -$16.80M -$15.70M $56.80M
YoY Change 42.37% -10.8% -452.8%
INVESTING ACTIVITIES
Capital Expenditures -$900.0K -$700.0K -$1.700M
YoY Change 350.0% 600.0% 1600.0%
Acquisitions
YoY Change
Other Investing Activities $28.80M -$26.40M -$82.60M
YoY Change 343.08% -181.99% 2073.68%
Cash From Investing Activities $28.00M -$27.10M -$84.40M
YoY Change 351.61% -184.42% 2064.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.30M 2.800M 79.00M
YoY Change -2560.0% 366.67%
NET CHANGE
Cash From Operating Activities -16.80M -15.70M 56.80M
Cash From Investing Activities 28.00M -27.10M -84.40M
Cash From Financing Activities 12.30M 2.800M 79.00M
Net Change In Cash 23.50M -40.00M 51.40M
YoY Change -485.25% -364.9% -357.0%
FREE CASH FLOW
Cash From Operating Activities -$16.80M -$15.70M $56.80M
Capital Expenditures -$900.0K -$700.0K -$1.700M
Free Cash Flow -$15.90M -$15.00M $58.50M
YoY Change 37.07% -14.29% -465.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Assets
Assets
286741000
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
11035000
CY2017Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5479000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
709000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
576377000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
44859000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13291000
CY2017Q4 sgmo Build To Suit Lease Obligations
BuildToSuitLeaseObligations
24738000
CY2016Q4 sgmo Build To Suit Lease Obligations
BuildToSuitLeaseObligations
3945000
CY2016Q4 us-gaap Liabilities
Liabilities
21696000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Goodwill
Goodwill
1585000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31066000
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6261000
CY2017Q4 us-gaap Liabilities
Liabilities
98841000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-54568000
CY2016Q4 us-gaap Assets
Assets
157891000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4145000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
29244000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4460000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
856000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1506000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1849000
CY2016Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2885000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
682809000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-440911000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-286000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
20000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
65728000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-14000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5722000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
78084000
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-306000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54874000
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4348000
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
911000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11730000
CY2015 sgmo Settlement Recognized As Additional Paid In Capital Net Of Tax
SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax
9495000
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
15099000
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
818000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
81573000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9089000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
997000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
988000
CY2016 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-221000
CY2015 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-827000
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-12000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
9089000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
169000
CY2017Q4 us-gaap Goodwill
Goodwill
1585000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4681000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
28345000
CY2015 us-gaap Interest And Other Income
InterestAndOtherIncome
431000
CY2016 us-gaap Operating Expenses
OperatingExpenses
91948000
CY2017 us-gaap Revenues
Revenues
36567000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-72559000
CY2016 us-gaap Revenues
Revenues
19389000
CY2017 us-gaap Revenue From Grants
RevenueFromGrants
607000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-54568000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
187900000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
136195000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
286741000
CY2016 sgmo Collaboration Agreements
CollaborationAgreements
18881000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
157891000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
85598534
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
85598534
CY2017 sgmo Collaboration Agreements
CollaborationAgreements
35960000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-495479000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70871902
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70871902
CY2016 us-gaap Revenue From Grants
RevenueFromGrants
508000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-56361000
CY2017 us-gaap Interest And Other Income
InterestAndOtherIncome
1793000
CY2016 us-gaap Interest And Other Income
InterestAndOtherIncome
887000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-71672000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
192439000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1498000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
673000
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
818000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15057000
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-481000
CY2016Q4 sgmo Assets Accumulated Gross Unrealized Loss Before Tax
AssetsAccumulatedGrossUnrealizedLossBeforeTax
26000
CY2017 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.14
CY2017 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
253994
CY2017 sgmo Stock Issued Under Employee Stock Purchase Plans Average Exercise Price
StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice
3.22
CY2016 sgmo Stock Issued Under Employee Stock Purchase Plans Average Exercise Price
StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice
4.04
CY2017 sgmo Employee Stock Purchase Plan Rights Weighted Average Estimated Fair Value
EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue
2.37
CY2016 sgmo Employee Stock Purchase Plan Rights Weighted Average Estimated Fair Value
EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue
2.27
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.10
CY2016 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8287456
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.77
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
15057000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
11730000
CY2015 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1800000
CY2015 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
2411000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-80904000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
19710000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
18125000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
77462000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
27765000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-47421000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
63452000
CY2015 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
1870000
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-14000
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-5722000
CY2017 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-80000
CY2016 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-99000
CY2017 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
16000
CY2016 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-83000
CY2015 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-116000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1629000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2144000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-7847000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
669000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1112000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-376000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3219000
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2335000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-764000
CY2017 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
2594000
CY2016 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
137000
CY2015 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-105000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
48984000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5214000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-8380000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
11179000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-65883000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-33720000
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
252328000
CY2016 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
218640000
CY2015 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
257988000
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
178675000
CY2016 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
237497000
CY2015 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
337861000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3751000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
732000
CY2017 us-gaap Payments For Leasing Costs
PaymentsForLeasingCosts
3500000
CY2017 sgmo Net Proceeds From Issuance Public Offering
NetProceedsFromIssuancePublicOffering
81573000
CY2017 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
654000
CY2016 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
776000
CY2015 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1546000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16571000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1113000
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6804000
CY2015 sgmo Proceeds From Claims Settlement
ProceedsFromClaimsSettlement
14452000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
97490000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
337000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69482000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6030000
CY2015 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.06
CY2015 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.06
CY2015 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
3000
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2017Q3 us-gaap Revenues
Revenues
11812000
CY2017Q4 us-gaap Revenues
Revenues
13077000
CY2016Q1 us-gaap Revenues
Revenues
3942000
CY2016Q2 us-gaap Revenues
Revenues
3702000
CY2016Q3 us-gaap Revenues
Revenues
2823000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
24847000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
26843000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
20623000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
30544000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
22029000
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
18752000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-12354000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-13091000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-16494000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-26575000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-18965000
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. During the fourth quarter of 2016, we revised our estimated performance period under the Bioverativ license agreement from June 2019 to June 2020, which also extended the recognition period of the related up-front payment we received upon entering this agreement (See Note 5). This change decreased revenues by $4.3 million and increased net loss and net loss per share by $0.06 for the year ended December 31, 2016. </p></div>
CY2017 sgmo Cash Equivalent Maturity Period Highly Liquid Investment
CashEquivalentMaturityPeriodHighlyLiquidInvestment
three months or less
CY2017 sgmo Minimum Percentage Of Likelihood Of Indefinite Lived Intangible Assets Being Impaired
MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired
0.50
CY2017Q4 sgmo Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber
8367628
CY2016Q4 sgmo Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber
9578322
CY2015Q4 sgmo Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber
9008185
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017Q4 sgmo Assets Amortized Cost
AssetsAmortizedCost
223634000
CY2016Q4 sgmo Assets Amortized Cost
AssetsAmortizedCost
139416000
CY2016Q4 sgmo Assets Accumulated Gross Unrealized Gain Before Tax
AssetsAccumulatedGrossUnrealizedGainBeforeTax
76000
CY2017Q4 sgmo Assets Accumulated Gross Unrealized Loss Before Tax
AssetsAccumulatedGrossUnrealizedLossBeforeTax
255000
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
223379000
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
139466000
CY2017 sgmo Investments Maturity Dates Available For Sale Securities
InvestmentsMaturityDatesAvailableForSaleSecurities
P2Y
CY2016 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2015 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2017Q4 sgmo Other Than Temporarily Impaired Investment
OtherThanTemporarilyImpairedInvestment
0
CY2016Q4 sgmo Other Than Temporarily Impaired Investment
OtherThanTemporarilyImpairedInvestment
0
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9089000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15057000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11730000
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
16100000
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M14D
CY2015 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
CY2017Q4 us-gaap Property Subject To Or Available For Operating Lease Number Of Units
PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits
3
CY2017 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
CY2017Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
8287456
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.72
CY2016 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
202711
CY2015 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
128181
CY2015 sgmo Stock Issued Under Employee Stock Purchase Plans Average Exercise Price
StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice
7.10
CY2015 sgmo Employee Stock Purchase Plan Rights Weighted Average Estimated Fair Value
EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue
4.42
CY2014Q1 sgmo Number Of Research Program
NumberOfResearchProgram
2
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16367000
CY2017 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y8M8D
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12048000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6951000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5639000
CY2017Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3881078
CY2017Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
8.99
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
321816
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
12300000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6400000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
71700000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
14000000
CY2017Q4 sgmo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue
1315000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-12000
CY2017Q4 sgmo Number Of Built To Suit Lease Properties
NumberOfBuiltToSuitLeaseProperties
2
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1100000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1000000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
900000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1685000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2925000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3795000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3798000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
3335000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
23896000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
39434000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017 sgmo Specified Stockholder Ownership Percentage
SpecifiedStockholderOwnershipPercentage
0.10
CY2017 sgmo Share Based Compensation Arrangement By Share Based Payment Award Purchase Price Of Common Stock Percent For Specified Stockholder
ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder
1.10
CY2017 sgmo Share Based Compensation Arrangement By Share Based Payment Award Options Maximum Term For Specified Stock Holder
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder
P5Y
CY2017Q4 sgmo Common Stock Exchange Ratio
CommonStockExchangeRatio
1.00
CY2017 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1.33
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9256506
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3091125
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2030815
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2029360
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8287456
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3881078
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.31
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.48
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.76
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.28
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.77
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.99
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M8D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y8M8D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y1M17D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
71658000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
71658000
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
28864000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
12600
CY2017 sgmo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod
112917
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
141327
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
80172
CY2017Q4 sgmo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber
80172
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P10M24D
CY2017 sgmo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm
P10M24D
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
1315000
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-2000
CY2015 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-159000
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-5563000
CY2016 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
-14000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5045000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
622000
CY2015 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
-5722000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-18553000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-24369000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-15785000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
795000
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-747000
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
4840000
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
53045000
CY2017 sgmo Income Tax Reconciliation Nondeductible Expense Income Share Based Compensation
IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation
2120000
CY2016 sgmo Income Tax Reconciliation Nondeductible Expense Income Share Based Compensation
IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation
2781000
CY2015 sgmo Income Tax Reconciliation Nondeductible Expense Income Share Based Compensation
IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation
1085000
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
869000
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1424000
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
814000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-36575000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
23773000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5043000
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
37000
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-28000
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-91000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
91308000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
114222000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
15147000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
12518000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3168000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
8565000
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
934000
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2918000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2276000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3492000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
112833000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
141715000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
112833000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
141715000
CY2015 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
-5000000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
23800000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
5000000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
475000000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
142000000
CY2017Q4 sgmo Deferred Tax Assets Tax Credit Carryforwards Research Federal
DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal
10800000
CY2017Q4 sgmo Deferred Tax Assets Tax Credit Carryforwards Research State And Local
DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal
11800000
CY2017 sgmo Federal Research Tax Credit Carryforward Expiration Year
FederalResearchTaxCreditCarryforwardExpirationYear
2018
CY2017 sgmo Tax Cuts And Jobs Act Of2017 Reduction Of Net Of Valuation Allowance
TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance
0
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017 sgmo Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
-8000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5659000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
8330000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1023000
CY2016 sgmo Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
27000
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
4335000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3438000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
557000
CY2015 sgmo Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
4335000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2580000
CY2017Q4 sgmo Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
7898000
CY2016Q4 sgmo Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2887000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1318000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
270000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
417000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
498000
CY2017Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
1386000
CY2016Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
26000
CY2017 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.50
CY2017 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.08
CY2016 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.06
CY2017 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.08
CY2016 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.06
CY2017 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
4000
CY2016 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
3000
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2017Q1 us-gaap Revenues
Revenues
3425000
CY2017Q2 us-gaap Revenues
Revenues
8253000
CY2016Q4 us-gaap Revenues
Revenues
8922000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
20217000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
21021000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-16632000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-12491000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2015Q3 sgmo Proceeds From Claims Settlement
ProceedsFromClaimsSettlement
14500000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-9624000

Files In Submission

Name View Source Status
0001564590-18-004163-index-headers.html Edgar Link pending
0001564590-18-004163-index.html Edgar Link pending
0001564590-18-004163.txt Edgar Link pending
0001564590-18-004163-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2018030121525117431123.jpg Edgar Link pending
g2018030121525133431431.jpg Edgar Link pending
g2018030121531013631431.jpg Edgar Link pending
g2018030121531014931432.jpg Edgar Link pending
g2018030121531016131433.jpg Edgar Link pending
g2018030121531033832030.jpg Edgar Link pending
g2018030121531034432031.jpg Edgar Link pending
g2018030121531049431434.jpg Edgar Link pending
g2018030121531377131123.jpg Edgar Link pending
g2018030121531380031124.jpg Edgar Link pending
g2018030121531381231125.jpg Edgar Link pending
g2018030121531680431126.jpg Edgar Link pending
g2018030121531683131127.jpg Edgar Link pending
g2018030121531685831128.jpg Edgar Link pending
g2018030121531689031129.jpg Edgar Link pending
g2018030121531707031130.jpg Edgar Link pending
g2018030121531709731131.jpg Edgar Link pending
g2018030121531712731132.jpg Edgar Link pending
g2018030121531715831133.jpg Edgar Link pending
g2018030121531718431134.jpg Edgar Link pending
g2018030121531720831135.jpg Edgar Link pending
g2018030121531722631136.jpg Edgar Link pending
g2018030121532351331435.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sgmo-10k_20171231.htm Edgar Link pending
sgmo-20171231.xml Edgar Link completed
sgmo-20171231.xsd Edgar Link pending
sgmo-20171231_cal.xml Edgar Link unprocessable
sgmo-20171231_def.xml Edgar Link unprocessable
sgmo-20171231_lab.xml Edgar Link unprocessable
sgmo-20171231_pre.xml Edgar Link unprocessable
sgmo-ex1013_620.htm Edgar Link pending
sgmo-ex1016_688.htm Edgar Link pending
sgmo-ex1021_830.htm Edgar Link pending
sgmo-ex102_368.htm Edgar Link pending
sgmo-ex1040_689.htm Edgar Link pending
sgmo-ex211_12.htm Edgar Link pending
sgmo-ex231_11.htm Edgar Link pending
sgmo-ex311_10.htm Edgar Link pending
sgmo-ex312_9.htm Edgar Link pending
sgmo-ex321_8.htm Edgar Link pending
Show.js Edgar Link pending